Literature DB >> 15983245

Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease.

Duncan J Campbell1, Mark Woodward, John P Chalmers, Samuel A Colman, Alicia J Jenkins, Bruce E Kemp, Bruce C Neal, Anushka Patel, Stephen W MacMahon.   

Abstract

BACKGROUND: B-type natriuretic peptide (BNP), C-reactive protein (CRP), and renin are elevated in persons at risk for cardiovascular disease. However, data that directly compare these markers in the prediction of myocardial infarction (MI) are limited. METHODS AND
RESULTS: N-terminal-proBNP (NT-proBNP), CRP, and renin were measured in baseline blood samples from a nested case-control study of the 6105 participants of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS), a placebo-controlled study of a perindopril-based blood pressure-lowering regimen among individuals with previous stroke or transient ischemic attack. Each of 206 subjects who experienced MI, either fatal or nonfatal, during a mean follow-up of 3.9 years was matched to 1 to 3 control subjects. Most MI cases (67%) occurred in subjects without a history of coronary heart disease. NT-proBNP, CRP, and renin each predicted MI; the odds ratio for subjects in the highest compared with the lowest quarter was 2.2 (95% CI, 1.3 to 3.6) for NT-proBNP, 2.2 (95% CI, 1.3 to 3.6) for CRP, and 1.7 (95% CI, 1.1 to 2.8) for renin. NT-proBNP and renin, but not CRP, remained predictors of MI after adjustment for all other predictors, including LDL and HDL cholesterol levels. Individuals with both NT-proBNP and renin in their highest quarters had 4.5 times the risk of MI compared with subjects with both biological markers in their lowest quarters.
CONCLUSIONS: NT-proBNP and renin, but not CRP, are independent predictors of MI risk after stroke or transient ischemic attack, providing information additional to that provided by classic risk factors, and may enable more effective targeting of MI prevention strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15983245     DOI: 10.1161/CIRCULATIONAHA.104.525527

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  Natriuretic peptides as markers of cardiovascular risk: the story continues.

Authors:  Hector O Ventura; Marc A Silver
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

Review 2.  Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

Authors:  Irmgard Tegeder; Gerd Geisslinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-04       Impact factor: 3.000

Review 3.  Now that we have a direct renin inhibitor, what should we do with it?

Authors:  Alice Stanton
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

4.  Plasmatic B-type natriuretic peptide and C-reactive protein in hyperacute stroke as markers of CT-evidence of brain edema.

Authors:  Pedro J Modrego; Beatriz Boned; Juan J Berlanga; Mercedes Serrano
Journal:  Int J Med Sci       Date:  2008-01-13       Impact factor: 3.738

Review 5.  Targeting cardiovascular protection: the concept of dual renin-angiotensin system control.

Authors:  Thomas Unger; Anne Jakobsen; Jose Heroys; Ann Ralph; Tomas Rees; Michael Shaw
Journal:  Medscape J Med       Date:  2008-03-26

6.  Plasma renin activity and its association with ischemic heart disease, congestive heart failure, and cerebrovascular disease in a large hypertensive cohort.

Authors:  John J Sim; Jiaxiao Shi; Rushdy Al-Moomen; Hind Behayaa; Kamyar Kalantar-Zadeh; Steven J Jacobsen
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-09-25       Impact factor: 3.738

7.  Interleukin-6, C-reactive protein, fibrinogen, and risk of recurrence after ischaemic stroke: Systematic review and meta-analysis.

Authors:  J J McCabe; E O'Reilly; S Coveney; R Collins; L Healy; J McManus; R Mulcahy; B Moynihan; T Cassidy; F Hsu; B Worrall; S Murphy; M O'Donnell; P J Kelly
Journal:  Eur Stroke J       Date:  2021-01-05

8.  Emerging drug combinations to optimize renovascular protection and blood pressure goals.

Authors:  Carlos Escobar; Rocio Echarri; Vivencio Barrios
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-04-03

9.  Plasma brain natriuretic peptide as a surrogate marker for cardioembolic stroke.

Authors:  Kazushi Yukiiri; Naohisa Hosomi; Takayuki Naya; Tsutomu Takahashi; Hiroyuki Ohkita; Mao Mukai; Hisashi Masugata; Koji Murao; Masaki Ueno; Takehiro Nakamura; Hiroaki Dobashi; Takanori Miki; Yasuhiro Kuroda; Masakazu Kohno
Journal:  BMC Neurol       Date:  2008-12-11       Impact factor: 2.474

Review 10.  The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction.

Authors:  Paolo Verdecchia; Fabio Angeli; Giovanni Mazzotta; Giorgio Gentile; Gianpaolo Reboldi
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.